RxDoctor Payments Data

Kay Siglos, MD

Internal Medicine · New York, NYNPI 1396053104

Payments from drug & device makers

$589in general payments, 2019–2025

Across 15 payments — averaging $39.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$164
  • GSK$123
  • Exact Sciences$61
  • AbbVie$48
  • Takeda Pharmaceuticals U.S.A., Inc.$43
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$35
  • plus $116 from 5 others

What the payments were for

  • Food & beverage$589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$589 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$237,212
Medicare patients
81
Services billed
4,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$40,885
OzempicSemaglutide34$35,376
JardianceEmpagliflozin20$26,735
MounjaroTirzepatide15$15,893
JanumetSitagliptin Phos/Metformin Hcl13$15,772
Tresiba Flextouch U-100Insulin Degludec15$6,776
SymbicortBudesonide/Formoterol Fumarate11$2,417
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,327
Atorvastatin Calcium154$1,263
Levothyroxine Sodium128$1,165
Albuterol Sulfate HfaAlbuterol Sulfate39$1,040
Gabapentin62$912
Trueplus Pen NeedlePen Needle, Diabetic16$909
Ventolin HfaAlbuterol Sulfate14$832
Omeprazole48$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$23$15,89315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →